Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy

Journal of Clinical Investigation

Volumn 110, Issue 10, 2002, Pages 1525-1538

  Yang, Junwei ^a   Shultz, Ryan W ^a   Mars, Wendy M ^a   Wegner, Rodney E ^a   Li, Yingjian ^a   Dai, Chunsun ^a   Nejak, Kari ^a   Liu, Youhua ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 3; FIBRONECTIN; GELATINASE B; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; GENE DISRUPTION; GENE EXPRESSION; GENE INDUCTION; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE BASEMENT MEMBRANE; KIDNEY TUBULE EPITHELIUM; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; URETER OBSTRUCTION;

EID: 0036854980     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0216219     Document Type: Article

References (62)

1. Eddy, A.A. 2000. Molecular basis of renal fibrosis. Pediatr. Nephrol. 15:290-301.
2. Lenz, O., Elliot, S.J., and Stetler-Stevenson, W.G. 2000. Matrix metalloproteinases in renal development and disease. J. Am. Soc. Nephrol. 11:574-581.
3. Yee, J.A., Yan, L., Dominguez, J.C., Allan, E.H., and Martin, T.J. 1993. Plasminogen-dependent activation of latent transforming growth factor beta (TGF beta) by growing cultures of osteoblast-like cells. J. Cell. Physiol. 157:528-534.
4. Mars, W.M., Zarnegar, R., and Michalopoulos, G.K. 1993. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am. J. Pathol. 143:949-958.
5. Border, W.A., and Noble, N.A. 1997. TGF-beta in kidney fibrosis: A target for gene therapy. Kidney Int. 51:1388-1396.
6. Matsumoto, K., and Nakamura, T. 2001. Hepatocyte growth factor: Renotropic role and potential therapeutics for renal diseases. Kidney Int. 59:2023-2038.
7. Liu, Y. 2002. Hepatocyte growth factor and the kidney. Curr. Opin. Nephrol. Hypertens. 11:23-30.
8. Port, F.K., Fenton, S.S.A., and Mazzuchi, N. 2000. ESRD throughout the world: Morbidity, mortality, and quality of life. Kidney Int. 57:S 1-S2.
9. Essawy, M., et al. 1997. Myofibroblasts and the progression of diabetic nephropathy. Nephrol. Dial. Transplant. 12:43-50.
10. Roberts, I.S., Burrows, C., Shanks, J.H., Venning, M., and McWilliam, L.J. 1997. Interstitial myofibroblasts: Predictors of progression in membranous nephropathy. J. Clin. Pathol. 50:123-127.
11. Powell, D.W., et al. 1999. Myofibroblasts. I. Paracrine cells important in health and disease. Am. J. Physiol. 277:C1-C9.
12. Liu, Y., Rajur, K., Tolbert, E., and Dworkin, L.D. 2000. Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways. Kidney Int. 58:2028-2043.
13. Fan, J.M., et al. 1999. Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int. 56:1455-1467.
14. Okada, H., Danoff, T.M., Kalluri, R., and Neilson, E.G. 1997. Early role of Fsp1 in epithelial-mesenchymal transformation. Am. J. Physiol. 273:F563-F574.
15. Strutz, F., et al. 1995. Identification and characterization of a fibroblast marker: FSP1. J. Cell Biol. 130:393-405.
16. Ng, Y.Y., et al. 1998. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int. 54:864-876.
17. Stahl, PJ., and Felsen, D. 2001. Transforming growth factor-beta, basement membrane, and epithelial-mesenchymal transdifferentiation: Implications for fibrosis in kidney disease. Am. J. Pathol. 159:1187-1192.
18. Strutz, F., et al. 2002. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int. 61:1714-1728.
19. Iwano, M., et al. 2002. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 110:341-350. doi:10.1172/JC1200215518.
20. Yang, J., and Liu, Y. 2001. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am. J. Pathol. 159:1465-1475.
21. Yang, J., Dai, C., and Liu, Y. 2001. Systemic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fibrosis in mice. Gene Ther. 8:1470-1479.
22. Kim, T.H., Mars, W.M., Stolz, D.B., Petersen, B.E., and Michalopoulos, G.K. 1997. Extracellular matrix remodeling at the early stages of liver regeneration in the rat. Hepatology. 26:896-904.
23. Pikul, S., et al. 1998. Discovery of potent, achiral matrix metalloproteinase inhibitors. J. Med. Chem. 41:3568-3571.
24. Oda, T., et al. 2001. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int. 60:587-596.
25. Kivirikko, K.I., Laitinen, O., and Prockop, D.J. 1967. Modifications of a specific assay for hydroxyproline in urine. Anal. Biochem. 19:249-255.
26. Liu, Y., et al. 1999. Up-regulation of hepatocyte growth factor receptor: An amplification and targeting mechanism for hepatocyte growth factor action in acute renal failure. Kidney Int. 55:442-453.
27. Vukicevic, S., et al. 1992. Reconstituted basement membrane (Matrigel) promotes the survival and influences the growth of murine tumors. Int. J. Cancer. 50:791-795.
28. Tisher, C.C., and Madsen, K.M. 1996. Anatomy of the kidney. In The Kidney. B.M. Brenner, editor. 5th edition. W.B. Saunders Co. Philadelphia, Pennsylvania, USA. 3-71.
29. Douthwaite, J.A, Johnson, T.S., Haylor, J.L., Watson, P., and El Nahas, A.M. 1999. Effects of transforming growth factor-beta 1 on renal extracellular matrix components and their regulating proteins. J. Am. Soc. Nephrol. 10:2109-2119.
30. Liu, Y. 1998. The human hepatocyte growth factor receptor gene: Complete structural organization and promoter characterization. Gene. 215:159-169.
31. Bissell, D.M., Roulot, D., and George, J. 2001. Transforming growth facfor beta and the liver. Hepatology. 34:859-867.
32. Steinmann-Niggli, K., Ziswiler, R., Kung, M., and Marti, H.P. 1998. Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis. J. Am. Soc. Nephrol. 9:397-407.
33. Lelongt, B., Legallicier, B., Piedagnel, R., and Ronco, P.M. 2001. Do matrix metalloproteinases MMP-2 and MMP-9 (gelatinases) play a role in renal development, physiology and glomerular diseases? Curr. Opin. Nephrol. Hypertens. 10:7-12.
34. Zeisberg, M., et al. 2001. Renal fibrosis: Collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am. J. Pathol. 159:1313-1321.
35. Zeisberg, M., Maeshima, Y., Mosterman, B., and Kalluri, R. 2002. Renal fibrosis. Extracellular matrix microenvironment regulates migratory behavior of activated tubular epithelial cells. Am. J. Pathol. 160:2001-2008.
36. Danen, E.H., and Yamada, K.M. 2001. Fibronectin, integrins, and growth control. J. Cell. Physiol. 189:1-13.
37. Yang, J., and Liu, Y. 2002. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J. Am. Soc. Nephrol. 13:96-107.
38. Okada, H., Inoue, T., Suzuki, H., Strutz, F., and Neilson, E.G. 2000. Epithelial-mesenchynial transformation of renal tubular epithelial cells in vitro and in vivo. Nephrol. Dial. Transplant. 15:44-46.
39. Strutz, F., and Muller, G.A. A. 2000. Transdifferentiation comes of age. Nephrol. Dial. Transplant. 15:1729-1731.
40. Li, J.H., et al. 2002. Smad7 inhibits fibrotic effect of TGF-beta on renal tubular epithelial cells by blocking smad2 activation. J. Am. Soc. Nephrol. 13:1464-1472.
41. Mars, W.M., Kim, T.H., Stolz, D.B., Liu, M.L., and Michalopoulos, G.K. 1996. Presence of urokinase in serum-free primary rat hepatocyte cultures and its role in activating hepatocyte growth factor. Cancer Res. 56:2837-2843.
42. Mizuno, K., Takehara, T., and Nakamura, T. 1992. Proteolytic activation of a single-chain precursor of hepatocyte growth factor by extracellular serine-protease. Biochem. Biophys. Res. Commun. 189:1631-1638.
43. Somerset, D.A., Strain, A.J., Afford, S., Whittle, M.D. 2000. Heparocyre growth factor activator (HGF-A) and its zymogen in human placenta. Placenta. 21:615-620.
44. Chevalier, R.L., Kim, A., Thornhill, B.A., and Wolstenholme, J.T. 1999. Recovery following relief of unilateral ureteral obstruction in the neonatal rat. Kidney Int. 55:793-807.
45. Chevalier, R.L., Thornhill, B.A., and Chang, A.Y. 2000. Unilateral ureteral obstruction in neonatal rats leads to renal insufficiency in adulthood. Kidney Int. 58:1987-1995.
46. Chevalier, R.L., Thornhill, B.A., Chang, A.Y., Cachat, F., and Lackey, A. 2002. Recovery from release of ureteral obstruction in the rat: Relationship to nephrogenesis. Kidney Int. 61:2033-2043.
47. Andrews, K.L., et al. 2000. Gelatinase B (MMP-9) is not essential in the normal kidney and does not influence progression of renal disease in a mouse model of Alport syndrome. Am. J. Pathol. 157:303-311.
48. Keverne, E.B. 1997. An evaluation of what the mouse knockout experiments are telling us about mammalian behaviour. Bioessays. 19:1091-1098.
49. Eddy, A.A., Kim, H., Lopez-Guisa, J., Oda, T., and Soloway, P.D. 2000. Interstitial fibrosis in mice with overload proteinuria: Deficiency of TIMP-1 is not protective. Kidney Int. 58:618-628.
50. Seeds, N.W., Basham, M.E., and Haffke, S.P. 1999. Neuronal migration is retarded in mice lacking the tissue plasminogen activator gene. Proc. Natl. Acad. Sci. USA. 96:14118-14123.
51. Siconolfi, L.B., and Seeds, N.W. 2001. Mice lacking tPA, uPA, or plasminogen genes showed delayed functional recovery after sciatic nerve crush. J. Neurosci. 21:4348-4355.
52. Brodsky, S., et al. 2001. Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis. Am. J. Physiol. Heart Circ. Physiol. 281:H1784-H1792.
53. Mori, T., et al. 2001. Reduced cortical injury and edema in tissue plasminogen activator knockout mice after brain trauma. Neuroreport. 12:4117-4120.
54. Ma, Z., Webb, D.J., Jo, M., and Gonias, S.L. 2001. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J. Cell Sci. 114:3387-3396.
55. Jo, M., Thomas, K.S., Somlyo, A.V., Somlyo, A.P., and Gonias, S.L. 2002. Cooperativity between the Ras-ERK and Rho-Rho kinase pathways in urokinase-type plasminogen activator-stimulated cell migration. J. Biol. Chem. 277:12479-12485.
56. Eddy, A.A. 2002. Plasminogen activator inhibitor-1 and the kidney. Am. J. Physiol. Renal. Physiol. 283:F209-F220.
57. Reilly, T.M., Greenplate, G., and Timmermans, P.B. 1989. Tissue plasminogen activator-induced secretion of type-1 plasminogen activator inhibitor in cultured human fibrolasts. Thromb. Res. 55:619-625.
58. Lau, H.K., and Ho, J. 2002. Regulation of plasminogen activator inhibitor-1 secretion by urokinase and tissue plasminogen activator in rat epithelioid-type smooth muscle cells. Br. J. Haematol. 117:151-158.
59. Tsirka, S.E., Rogove, A.D., Bugge, T.H., Degen, J.L., and Strickland, S. 1997. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J. Neurosci. 17:543-552.
60. Rogove, A.D., Siao, C., Keyt, B., Strickland, S., and Tsirka, S.E. 1999. Activation of microglia reveals a non-proteolytic cytokine function for tissue plasminogen activator in the central nervous system. J. Cell Sci. 112:4007-4016.
61. Nakamura, T., et al. 1989. Molecular cloning and expression of human hepatocyte growth factor. Nature. 342:440-443.
62. Han, S, Stuart, L.A., and Degen, S.J. 1991. Characterization of the DNF1SS2 locus on human chromosome 3: Identification of a gene coding for four kringle domains with hamology to hepatocyte growth factor. Biochemistry. 30:9768-9780.